YAP1 and cholangiocarcinoma: Analysis of ChIP-seq datasets revealed robust binding of YAP and TEAD to sequences downstream of NUAK231,37,38, in human cholangiocarcinoma (Fig. 1c), mesothelioma (Fig. 1d), breast adenocarcinoma, glioblastoma, and fetal lung cell lines (Supplementary Fig. 1a).